HUANG Ling,WANG Fengling,CHEN Li,et al.Mining and analysis of risperidone adverse event signals based on FAERS database[J].ZHONGGUO YAOFANG,2023,34(03):350-354.
HUANG Ling,WANG Fengling,CHEN Li,et al.Mining and analysis of risperidone adverse event signals based on FAERS database[J].ZHONGGUO YAOFANG,2023,34(03):350-354. DOI: 10.6039/j.issn.1001-0408.2023.03.18.
Mining and analysis of risperidone adverse event signals based on FAERS database
To provide reference for safe use of risperidone in clinic.
METHODS
2
Data mining and analysis of risperidone-related adverse drug event (ADE) reports from the first quarter of 2017 to the third quarter of 2021 in the United States FAERS database were carried out using reported odds ratio and composite criteria methods from Medicines and Healthcare Products Regulatory Agency.
RESULTS
2
There were 101 181 ADE reports with risperidone as the primary suspect drug,involving a total of 33 179 patients. Among those reports,the male-to-female ratio was about 6.21 to 1; most of them were <18 years old (15.01%); ADE was mainly reported by consumers (69.74%) and mainly reported by the United States (79.72%); oral dosage form was the most used,accounting for 83.71%. A total of 409 ADE signals were obtained,including male breast development,pseudogynecomastia,abnormal increase in body mass,hyperprolactinemia and Wellens syndrome,etc. Twenty-six systems and organs were involved,mainly including reproductive system and breast diseases,various injuries,poisoning and operational complications,mental diseases,metabolic and nutritional diseases,and various nervous system diseases,etc.
CONCLUSIONS
2
The common ADE signals of risperidone and the system involved are consistent with the instructions,but we should also be alert to the ADE not recorded in the instruction,such as Wellens syndrome,fibroproliferative endocarditis,cavernous degeneration of portal vein,rabbit syndrome,etc.
关键词
利培酮药品不良事件信号数据挖掘药品不良反应
Keywords
adverse drug eventssignaldata miningadverse drug reaction
references
ARIAS D,SAXENA S,VERGUET S. Quantifying the global burden of mental disorders and their economic value[J]. EClinicalMedicine,2022,54:101675.
GERMANN D,KURYLO N,HAN F X. Risperidone[J]. Profiles Drug Subst Excip Relat Methodol,2012,37:313-361.
RICHARD F,LUIGI X C,MICHELLE A C.图解药理学:中文翻译版[M]. 罗俊,译. 北京:科学出版社,2014:137-142.
CHOPKO T C,LINDSLEY C W. Classics in chemical neuroscience:risperidone[J]. ACS Chem Neurosci,2018,9(7):1520-1529.
MÖLLER H J. Risperidone:a review[J]. Expert Opin Pharmacother,2005,6(5):803-818.
HUANG M L,VAN PEER A,WOESTENBORGHS R,et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects[J]. Clin Pharmacol Ther,1993,54(3):257-268.
KOMOSSA K,RUMMEL-KLUGE C,SCHWARZ S,et al. Risperidone versus other atypical antipsychotics for schizophrenia[J].Cochrane Database Syst Rev,2011,21(1):CD006626.
LEE B H. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients[J]. Prog Neuro Psychopharmacol Biol Psychiatry,2006,30(4):658-662.
TURRONE P,KAPUR S,SEEMAN MV,et al. Elevation of prolactin levels by atypical antipsychotics[J]. Am J Psychiatry,2002,159(1):133-135.
TROOST P W,LAHUIS B E,HERMANS M H,et al. Prolactin release in children treated with risperidone:impact and role of CYP2D6 metabolism[J]. J Clin Psychopharmacol,2007,27(1):52-57.
LIU J H,WANG P P,SUN L L,et al. The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients:a 12-week prospective study[J]. Transl Psychiatry,2021,11(1):458.
BROWN H K,et al. Perinatal mental illness and maternal autoimmune disease:a review of current evidence and avenues for future research[J]. Front Neuroendocrinol,2022,65:100975.
WANG Z X,BRAUER R,MAN K K C,et al. Prenatal exposure to antipsychotic agents and the risk of congenital malformations in children:a systematic review and meta-analysis[J]. Br J Clin Pharmacol,2021,87(11):4101-4123.
ENNIS Z N,DAMKIER P. Pregnancy exposure to olanzapine,quetiapine,risperidone,aripiprazole and risk of congenital malformations. A systematic review[J]. Basic Clin Pharmacol Toxicol,2015,116(4):315-320.
LARSEN ER,DAMKIER P,PEDERSEN LH,et al. Use of psychotropic drugs during pregnancy and breast-feeding[J]. Acta Psychiatr Scand Suppl,2015,132(S445):1-28.
KEITH S. Use of long-acting risperidone in psychiatric disorders:focus on efficacy,safety and cost-effectiveness[J]. Expert Rev Neurother,2009,9(1):9-31.
PEUSKENS J,PANI L,DETRAUX J,et al. The effects of novel and newly approved antipsychotics on serum prolactin levels:a comprehensive review[J]. CNS Drugs,2014,28(5):421-453.
LOVE R C,CONLEY R J. Long-acting risperidone injection[J]. Am J Health Syst Pharm,2004,61(17):1792-1800.
Mining and analysis of adverse drug event signals related to mepolizumab
Pharmaceutical analysis for a patient with rebamipide-induced Stevens-Johnson syndrome by clinical pharmacists
我院1 557 例药品不良反应报告分析
我院1557例药品不良反应报告分析
我院609例药源性皮疹病例分析
Related Author
CHEN Yaoxin
WU Shaoxing
LI Haoxuan
XU Yinji
GONG Wenjun
ZOU Jian
XU Han
BIAN Yuan
Related Institution
The Second Clinical Medical College, Guangzhou University of Chinese Medicine
Dept. of Respiratory and Critical Care Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine
Dept. of Clinical Pharmacy,Pengzhou Municipal People’s Hospital, Sichuan Pengzhou
Dept. of Clinical Pharmacy,the Affiliated Zigong Hospital of Southwest Medical University
Personalized Drug Therapy Key Laboratory of Sichuan Province, Dept. of Pharmacy of Sichuan Academy of Medical Sciences·Sichuan Provincial People’s Hospital/Affiliated Hospital of University of Electronic Science and Technology